Our TLR7 lead candidate MBS8 is a micelle formulation of a small molecule TLR7 agonist with the unique selling points:
- Administered by the intravenous route to target multiple cancer types
- Targeting the intracellular TLR7 receptor
- Simple and scalable GMP production
- Potent anti-tumor activity as monotherapy and in combination with anti-PD-1, radiotherapy and chemotherapy
- Favourable safety profile
